UK’s NICE Changes Stance on New Osteoporosis Drug
The novel osteoporosis drug Evenity can be prescribed on the NHS, according to NICE. The move is a reversal of [...]
ICR: NICE Reforms Fall Short of Increasing Access to Innovative Cancer Treatments
The Institute of Cancer Research (ICR), London, is not satisfied with The National Institute of Health and Care Excellence’s (NICE) [...]
Dr. Samantha Roberts Announced as New NICE Chief Executive
NICE has announced that Dr. Samantha Roberts, currently Managing Director for Health and Care at Legal and General, will take [...]
NICE’s 5-Year Strategy Signals a More Collaborative Approach.
The UK’s National Institute for Health and Care Excellence (NICE) new health technology assessment manual signals a push towards greater [...]
New Depression Guidelines Released by NICE
The UK’s National Institute of Care and Excellence (NICE) has released their new guidance for depression diagnosis, treatment, and management. [...]
Changing Dynamics Between NICE and Pharmaceutical Industry
Recent shifts in the UK’s National Institute for Health and Care Excellence’s (NICE) approach to health technology assessment (HTA) are [...]
Cochrane Deputy Editor in Chief Discusses New Partnership with NICE
Cochrane and the National Institute for Health and Care Excellence (NICE) have announced a partnership to share in-progress articles for [...]
NICE Begins Construction of RWE Framework, Turns to Aetion for Guidance in Recent Collaboration
The National Institute for Health and Care Excellence (NICE) has begun working on new guidelines that will inform pharmaceutical companies [...]
Aetion and NICE Partner to Leverage RWE in Comparative Effectiveness Studies
Aetion and the National Institute for Health and Care Excellence (NICE) have announced a partnership intended to advance comparative effectiveness [...]
NICE Technical Director Discusses RWE and HEOR Careers and Key Trends
Jacoline Bouvy of the National Institute for Health and Care Excellence (NICE) discussed key trends in health economics and outcomes [...]
NICE’s Accelerated Drug Approval Process Aims to Overcome COVID-19 Delays
The UK’s National Institute for Health and Care Excellence (NICE) has announced an accelerated approval process that is intended to [...]
NICE Upholds Rejection of Expensive Cancer Drug as Calls for Flexible Drug Pricing Models Grow
The National Institute for Health and Care Excellence (NICE) has rejected Zytiga for the second time. Despite evidence that the [...]
Register Today for ISPOR Webinar on NICE’s Strategic Approach to RWE and Novel Therapy Approval
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s next installment of its Signal series will take place July 15th [...]
Upcoming ISPOR Webinar on NICE’s Modernized Data Handling Methods and 5-Year Strategy
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold a virtual event on July 15th at 11:00 AM [...]
NICE Policy Leader Discusses RWE Trends and Global Impact of COVID-19
The UK’s National Institute for Health and Care Excellence (NICE) recently put forth a five-year strategy plan where it includes guidelines [...]
HTA Whitepaper Discusses Resulting Value and Economic Benefits
In a whitepaper by researchers at the USC Schaeffer Center and Aspen Institute Advisory Panel, the authors discuss how an [...]
NICE Issues Ruling on Bladder Cancer Drug Keytruda
MSD’s Keytruda (pembrolizumab) is a second-line bladder cancer drug. It has been shown to improve survival. However, it has not [...]
Novartis and NHS England Agree on Price of Costly SMA Drug; Zolgensma Nearly £1.8 Million per Dose
SMA (spinal muscular atrophy) is characterized by muscle weakness, paralysis, and eventual loss of movement. It is associated with extremely [...]
The US FDA Has a Different Rubric for Cancer Drug Approval Than the UK and Canada
Different regulatory bodies have different criteria when it comes to drug approval, especially in the case of cancer drugs. The [...]
NICE rejects MS drug Zeposia Citing Cost Concerns
Bristol Myers Squibb developed Zeoposia (ozanimod) for use in multiple sclerosis patients. NICE (National Institute for Health and Care Excellence) [...]
NICE Updates Methods for Health Technology Evaluations
On November 6, 2020, NICE published a summary of its proposed changes to health technology evaluation methods. NICE periodically assesses its methods [...]
Response to NICE Methods of Health Technology Evaluation
NICE recently posted a consultation entitled "The NICE methods of health technology evaluation: the case for change". which detailed its [...]
The NICE methods of health technology evaluation: the case for change
NICE recently posted a consultation entitled "The NICE methods of health technology evaluation: the case for change" which details its [...]
UK’s NICE Becomes Single Access Point for Covid-19 Guidance
The National Institute for Health and Care Excellence (NICE) announced that will it host a new, single point of advice [...]
Incentivizing Novel Antibiotic Development–Netflix-Style
Drug makers have been increasingly disincentivized from developing novel antibiotics due to higher development costs and antibiotic stewardship programs, resulting [...]